How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,389 results for

Cerebrovascular Accident Risk in Women

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

disease which may require treatment with surgery or radiation therapy) Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial within 6 months prior to randomization Venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks) within 6 months prior to randomization Clinically significant ventricular arrhythmias within 6 months prior to randomization Metastatic prostate cancer Baseline moderate or severe (...) Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer

2016 Clinical Trials

62. Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria Male or female patients at least 18 years of age. Patients currently on oral anticoagulation treatment with VKA of coumadin or warfarin type. Patients being admitted to the hospital or currently hospitalized where: an urgent surgery carrying significant bleeding risk (≥50 mL expected blood loss) is required (...) stenosis, cerebrovascular accident, transient ischemic attack, severe peripheral vascular disease, or disseminated intravascular coagulation within 3 months of enrollment. Patients with a known congenital bleeding disorder. Patients with a known antiphospholipid antibody syndrome. Patients with present or past specific factor inhibitor activity. Patients with thrombocytopenia of <80,000/μL or history of heparin-induced thrombocytopenia. Patients who have received heparin of any type or any non-VKA

2016 Clinical Trials

63. ARN-509 and Leuprolide in Intermediate and High-risk Prostate Cancer

-hypertensive therapy. Have a known history of pituitary or adrenal dysfunction Have clinically significant heart disease as evidenced by severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to randomization Have a history of gastric bypass surgery or severe malabsorption (...) ARN-509 and Leuprolide in Intermediate and High-risk Prostate Cancer ARN-509 and Leuprolide in Intermediate and High-risk Prostate Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. ARN-509

2016 Clinical Trials

64. AASUR in High Risk Prostate Cancer

, rifapentine, phenobarbital) Major surgery within 4 weeks of registration Presence of a pacemaker Active infection or other medical condition that would make prednisone use contraindicated A known hypersensitivity to abiraterone acetate, apalutamide, and prednisone and/or any of their excipients Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic (...) AASUR in High Risk Prostate Cancer AASUR in High Risk Prostate Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. AASUR in High Risk Prostate Cancer The safety and scientific validity of this study

2016 Clinical Trials

65. Risk-Factor Profile and Comorbidities in 2398 Patients With Newly Diagnosed Hypertension From the Abuja Heart Study. Full Text available with Trip Pro

oedema in 468 (19.5%), paroxysmal nocturnal dyspnoea in 332 (13.8%), whereas only 31 (1.3%) presented with chest pain. Risk factors were obesity in 671 (28%); 523 (21.8%) had total cholesterol >5.2 mmol/L, diabetes mellitus was present in 201 (8.4%) and 187 (7.8%) were smokers. End-organ damage was present in form of echocardiographic left ventricular hypertrophy in 1336 (55.7%) followed by heart failure in 542 (22.6%). Arrhythmias occurred in 110 (4.6%) of cases, cerebrovascular accident in 103 (4.3 (...) Risk-Factor Profile and Comorbidities in 2398 Patients With Newly Diagnosed Hypertension From the Abuja Heart Study. Risk factors, comorbidities, and end-organ damage in newly diagnosed hypertension (HT) are poorly described in larger cohorts of urban African patients undergoing epidemiological transition. We therefore decided to characterize a large cohort of hypertensive subjects presenting to a tertiary health center in sub-Saharan Africa. It is an observational cross-sectional study. We

2015 Medicine

66. Diagnostic Imaging Strategies for Patients With Stable Chest Pain and Intermediate Risk of Coronary Artery Disease

closure of vessels, stent infection. Occurrence of other adverse events and serious adverse events in the Invasive Coronary Angiography group [ Time Frame: during ICA examination, up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow-up to a maximum of 4 years ] Composite outcome: Occurrence of other adverse events (AEs) and serious adverse events (SAEs) such as heart failure, cardiogenic shock, cerebrovascular accident (CVA)/Stroke, hemorrhagic (...) Diagnostic Imaging Strategies for Patients With Stable Chest Pain and Intermediate Risk of Coronary Artery Disease Diagnostic Imaging Strategies for Patients With Stable Chest Pain and Intermediate Risk of Coronary Artery Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2015 Clinical Trials

67. Metformin for Preventing Frailty in High-risk Older Adults

of nursing home or long-term care facility Subjects with diabetes based on American Diabetes Association criteria or currently taking glucose lowering medications Subjects taking drugs known to affect glucose homeostasis Untreated depression or Geriatric Depression Scale score on 15-item scale >7 Diagnosis of any disabling neurologic disease Parkinson's Disease, Amyotrophic Lateral Sclerosis, multiple sclerosis, cerebrovascular accident with residual deficits (muscle weakness or gait disorder), diagnosis (...) Metformin for Preventing Frailty in High-risk Older Adults Metformin for Preventing Frailty in High-risk Older Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Metformin for Preventing Frailty in High

2015 Clinical Trials

68. Low density lipoprotein cholesterol control status among Canadians at risk for cardiovascular disease: findings from the Canadian Primary Care Sentinel Surveillance Network Database Full Text available with Trip Pro

Surveillance Network (CPCSSN) database were studied. The Framingham-Risk-Score was calculated to determine the risk levels. A serum LDL-C level of >2.0 mmol/L was considered as being poorly controlled. Patients with a previous record of a cerebrovascular accident, peripheral artery disease, or an ischemic heart disease were regarded as those under secondary prevention. Logistic regression modeling was performed to examine the factors associated with the LDL-C control.A total of 6,405 high-risk patients (...) Low density lipoprotein cholesterol control status among Canadians at risk for cardiovascular disease: findings from the Canadian Primary Care Sentinel Surveillance Network Database To determine the prevalence of uncontrolled LDL-C in patients with high cardiovascular disease (CVD) risks across Canada and to examine its related factors.Non-pregnant adults >20 years-old, who had a lipid test completed between January 1, 2009 and December 31, 2011 and were included in the Canadian Primary Care

2015 Lipids in health and disease

69. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study Full Text available with Trip Pro

aged 12 to 50 years for whom combined oral contraceptives had been dispensed between Jan. 1, 2002, and Dec. 31, 2008. We followed the cohort until 2009. We used Poisson regression models to estimate the crude and adjusted rate ratios for risk factors for venous thrombotic events (specifically deep vein thrombosis and pulmonary embolism) and arterial thromboic events (specifically transient ischemic attack and cerebrovascular accident). We performed multivariable analyses to compare types (...) Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study Combined oral contraceptives are a common method of contraception, but they carry a risk of venous and arterial thrombosis. We assessed whether use of drospirenone was associated with an increase in thrombotic risk relative to third-generation combined oral contraceptives.Using computerized records of the largest health care provider in Israel, we identified all women

2012 EvidenceUpdates

70. Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women

to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12. Secondary Efficacy Endpoints - Female Sexual Function (...) total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12. Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Desire [ Time Frame: Baseline and Week 12 ] Change from Baseline to Week 12 in FSFI Domain Score (Desire) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4

2014 Clinical Trials

71. Primary Care Corner with Geoffrey Modest MD: CPAP Does Not Reduce Cardiovasc Risk

Primary Care Corner with Geoffrey Modest MD: CPAP Does Not Reduce Cardiovasc Risk Primary Care Corner with Geoffrey Modest MD: CPAP Does Not Reduce Cardiovasc Risk | BMJ EBM Spotlight by By Dr. Geoffrey Modest A recent article looked at patients with moderate-to-severe obstructive sleep apnea (OSA) and documented cardiovascular disease (CVD), finding no reduced risk of adverse cardiovascular outcomes by using CPAP (see DOI: 10.1056/NEJMoa1606599). Details: 2717 patients aged 45-75 who had (...) moderate-to-severe OSA as well as coronary or cerebrovascular disease were randomized to receive CPAP treatment plus usual care (CPAP group) or usual care alone (usual-care group) Mean age 61, 81% male, 64% Asian/25% white, 51% with coronary artery disease/49% cerebrovascular disease, 79% hypertensive, 44% stroke, 33% MI, 30% diabetic, 15% smokers, 78% on BP meds/57% statins/75% aspirin/27% diabetic meds, BMI 29, apnea-hypopnea index (AHI) 29 (moderate-to-severe obstructive sleep apnea), 84% snoring

2016 Evidence-Based Medicine blog

72. Laparoscopic Sleeve Gastrectomy Plus Weight Watchers vs. Weight Watchers Alone in Underserved Minority Women

history of scleroderma, amyloidosis Thyroid disease which is not controlled with medication Hormonal or genetic cause for the obese state. History of cancer other than localized basal cell carcinoma. Myocardial infarction or cerebrovascular accident within past year. Angina pectoris. Severe coagulopathy (prothrombin time > 3 seconds over control or platelet count < 100,000) Gastroparesis or pyloric stenosis. Lesions with increased risk of bleeding. Severe cardiopulmonary disease or other serious (...) Laparoscopic Sleeve Gastrectomy Plus Weight Watchers vs. Weight Watchers Alone in Underserved Minority Women Laparoscopic Sleeve Gastrectomy Plus Weight Watchers vs. Weight Watchers Alone in Underserved Minority Women - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2013 Clinical Trials

73. Relation of Carotid Intima-Media Thickness and Plaque With Incident Cardiovascular Events in Women With Systemic Lupus Erythematosus. Full Text available with Trip Pro

Relation of Carotid Intima-Media Thickness and Plaque With Incident Cardiovascular Events in Women With Systemic Lupus Erythematosus. Patients with systemic lupus erythematosus (SLE) are at increased risk for cardiovascular (CV) disease. The aim of this study was to investigate the association between subclinical CV disease as measured by carotid intima-media thickness (IMT) and plaque using B-mode carotid ultrasound and incident CV events in a combined cohort of female patients with SLE (...) . This was a prospective, 2-center observational study of 392 adult women with SLE and no previous CV events with a mean 8 years of follow-up. Incident CV events confirmed by clinicians were defined as angina, myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass graft, fatal cardiac arrest, transient ischemic attack, and cerebrovascular accident. Incident hard CV events excluded angina and transient ischemic attack. The mean age was 43.5 years, and most patients were Caucasian

2013 American Journal of Cardiology

74. Cardiovascular Risk in Asymptomatic Adults: Guideline For Assessment of

. USEFULNESS IN MOTIVATING PATIENTS, GUIDING THERAPY, AND IMPROVING OUTCOMES e84 2.6.2. Special Considerations: Women e84 2.6.2.1. RECOMMENDATIONS FOR SPECIAL CONSIDERATIONS IN WOMEN e84 2.6.2.2. DETECTION OF WOMEN AT HIGH RISK USING TRADITIONAL RISK FACTORS AND SCORES e84 2.6.2.3. COMPARABLE EVIDENCE BASE FOR RISK STRATIFICATION OF WOMEN AND MEN e84 2.6.3. Ethnicity and Race e85 2.6.4. Older Adults e85 2.6.5. Chronic Kidney Disease e85 3. Future Research Needs e85 3.1. Timing and Frequency of Follow-Up (...) is the leading cause of death for both men and women in the United States (3). Risk factors for the development of atherosclerotic disease are widespread in the U.S. population. In 2003, approximately 37% of Amer- ican adults reported having2 risk factors for CVD. Ninety percent of patients with coronary heart disease (CHD) have at least 1 atherosclerotic risk factor (4). Approximately half of all coronary deaths are not preceded by cardiac symptoms or diagnoses (5). One aim of this guideline is to provide

2010 American College of Cardiology

75. A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia

injury within 28 days before start of chemotherapy. Active cardiac disease Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months before start of chemotherapy. Ongoing infection, known history of human immunodeficiency virus (HIV) infection, tuberculosis, or chronic hepatitis B or C. Patients with evidence or history of bleeding diathesis. Non-healing wound, ulcer or bone (...) A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer

2014 Clinical Trials

76. Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma

mmHg or diastolic pressure > 90 mmHg, despite optimal medical management Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months Pulmonary hemorrhage/bleeding event >= CTCAE grade 2 within 4 weeks of first dose of study drug Any other hemorrhage/bleeding event >= CTCAE grade 3 within 4 weeks of first dose of study drug Serious non-healing wound, ulcer (...) Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save

2014 Clinical Trials

77. Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation

of childbearing potential must use acceptable methods of birth control throughout the study as described below: Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment. Men should use adequate birth control for at least 30 days after the last administration of sorafenib. Post-menopausal women (defined as no menses for at least one year) and surgically sterilized women are not required to undergo a pregnancy test. Females of childbearing (...) . Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months. Pulmonary hemorrhage/bleeding event > or equal to CTCAE v4. Grade 2 within 4 weeks of first dose of study drug. Any other hemorrhage/bleeding event > or equal to CTCAE v4. Grade 3 within 4 weeks of first dose of study drug. Serious non-healing wound, ulcer, or bone fracture. Evidence of bleeding diathesis or coagulopathy within the past 6 months. Known or suspected allergy

2014 Clinical Trials

78. Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F and T121E02F in Healthy Postmenopausal Women

. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 35 Years to 70 Years (Adult, Older Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Healthy, postmenopausal women between the ages of 35 and 70 years, inclusive. Postmenopausal females (based on medical history) defined as 12 continuous (...) significant cardiovascular (CV) disease or condition, including: Any history of a major CV event (myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack); Any history of a significant cardiac arrhythmia, implanted artificial pacemaker; Blood pressure greater than 150/90 and heart rate greater than 100 at screening; Clinically significant abnormalities on 12-lead ECG, including QTc >450 msec (heart-rate corrected using the Fridericia formula) at Screening. History

2012 Clinical Trials

79. Efficacy and Safety of Oral NOMAC-E2 in Indian Women (P07057/MK-8175A-017)

Criteria: Sexually active and at risk for pregnancy Of Indian descent, born in India, never emigrated out of India, with Indian home address Body mass index (BMI) ≥17 and ≤35 kg/m^2 Exclusion Criteria: Presence or history of venous or arterial thrombotic/thromboembolic events or cerebrovascular accident Presence or history of prodromi of a thrombosis History of migraine with focal neurological symptoms Diabetes mellitus with vascular involvement Presence of a severe or multiple risk factor(s (...) Efficacy and Safety of Oral NOMAC-E2 in Indian Women (P07057/MK-8175A-017) Efficacy and Safety of Oral NOMAC-E2 in Indian Women (P07057/MK-8175A-017) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy

2012 Clinical Trials

80. Evaluation of Cardiovascular Diseases and Their Risk Factors in Hospitalized Patients in East Azerbaijan Province, Northwest Iran: A Review of 18323 Cases Full Text available with Trip Pro

-Q3) ages of the males and females were 59 (49-70) and 62 (51-71) years, respectively. Ischemic heart diseases were diagnosed in 68.4%, electrophysiological disorders in 6.5%, and valvular heart diseases in 4.5% of the patients. The frequencies of the studied risk factors were as follows: cigarette smoking (47.5%); hypertension (66.95%); diabetes mellitus (35.9%); and history of cerebrovascular accident (16.4%) and renal disease (13.4%). Medical therapy was performed in 79.23%, surgery in 6.28 (...) hospitalized due to cardiovascular diseases were collected to evaluate the diseases and their risk factors in 15 hospitals in the East Azerbaijan Province, northwest Iran. We assessed the main diagnosis of cardiovascular disease on admission in each hospital. Also, types of interventional and surgical procedures were assessed and all these variables were compared between men and women.The study population consisted of 56.6% male and 43.4% female patients. The median and range between quartile 1 and 3 (Q1

2013 The Journal of Tehran University Heart Center

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>